All tests were done on 6 tablets of each formulation and the mean of results was selleck products considered in release profiles. 2.6. Budesonide Analysis The quantitative determination of budesonide in assay and dissolution studies was performed by HPLC method equipped with UV detector using dexamethasone as an internal standard. The analysis was carried out by using a Shimpack C8 column (150mm × 4.6mm, 5mm particle size) at a wavelength of 244nm. The mobile phase consisted of acetonitrile,
monobasic potassium phosphate (0.025M) (55:45, pH of 3.2). The flow rate was 1.0mL/min and injection volume, 20μL. Quantitation was achieved by measurement of the peak area ratios of the drug to the internal standard. The retention Inhibitors,research,lifescience,medical time of the budesonide chromatographic peak was found at 5min. 2.7. Stability Studies Optimized Inhibitors,research,lifescience,medical formulation was kept in the humidity chamber maintained at 40°C and 75% relative humidity for 3 months. At the end of study, the formulation was evaluated for drug content and in vitro release profile. 2.8. Statistical Analysis The data of drug release were analyzed using one-way analysis of variance (ANOVA). The release profiles of optimized formulation were compared in stability and reproducibility Inhibitors,research,lifescience,medical tests using model-independent
approach, with the similarity factor (f2) defined by : f2=50+log[1+ (1n)∑t=1nn(Rt−Tt)2]−0.5×100. (1) The two release profiles Inhibitors,research,lifescience,medical were considered to be similar if f2 value was more than 50 (between 50 and 100). 3. Results and Discussion During this study, budesonide pellet core formulation was developed using extrusion-spheronization technique. These pellets were spherical in shape and showed suitable hardness to withstand coating conditions. The pellets Inhibitors,research,lifescience,medical had a 91 ± 2.83% budesonide release after 2hrs in pH 6.8, so any later slow release could be attributed to the coating system(s) being studied. 3.1. In Vitro Drug Release from Coated Pellets In designing an ideal colon-targeted drug delivery system, the drug should not
be released in the stomach and small intestine, and the release of drug must be completed within the residence time of the dosage form in the colon. In the case of the present study, it was assumed that for colon-targeting purpose, an 18 h extended release formulation Carfilzomib with a delay in onset of about 6h would be suitable. This lag time would ensure the passage of the formulation intact through the stomach and small intestine without noticeable drug loss. The approach of using mixed polymeric coating of Eudragit NE 30D and Eudragit L30D-55 blends in time release applications has been reported previously . Eudragit NE30D is an acrylic copolymer with neutral groups that enables sellckchem controlled time release of the active ingredient by pH-independent swelling . As its softening temperature is ca.